Leczenie podtrzymujące w szpiczaku plazmocytowym
-
Published:2013-04
Issue:2
Volume:44
Page:116-123
-
ISSN:0001-5814
-
Container-title:Acta Haematologica Polonica
-
language:pl
-
Short-container-title:Acta Haematologica Polonica
Author:
Grosicki Sebastian
Publisher
Walter de Gruyter GmbH
Subject
Oncology,Hematology
Reference29 articles.
1. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management;Rajkumar;Am J Hematol.,2012
2. Dutch-Belgian Hemato-Oncology Group (HOVON). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma;Lokhorst;Blood.,2010
3. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis;Morgan;Blood.,2012
4. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial;Palumbo;J Clin Oncol.,2010
5. The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens;Benevolo;Cancer.,2011